CN115444893A - Active substance composition for reducing uric acid and application thereof - Google Patents
Active substance composition for reducing uric acid and application thereof Download PDFInfo
- Publication number
- CN115444893A CN115444893A CN202211071108.0A CN202211071108A CN115444893A CN 115444893 A CN115444893 A CN 115444893A CN 202211071108 A CN202211071108 A CN 202211071108A CN 115444893 A CN115444893 A CN 115444893A
- Authority
- CN
- China
- Prior art keywords
- leaf extract
- uric acid
- ampelopsis grossedentata
- active substance
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 73
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 229940116269 uric acid Drugs 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000001603 reducing effect Effects 0.000 title claims abstract description 26
- 239000013543 active substance Substances 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 117
- 241001018563 Nekemias grossedentata Species 0.000 claims abstract description 79
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 61
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 61
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 60
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 16
- 210000002966 serum Anatomy 0.000 abstract description 10
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 abstract description 7
- 229950000193 oteracil Drugs 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 108010093894 Xanthine oxidase Proteins 0.000 description 21
- 102100033220 Xanthine oxidase Human genes 0.000 description 21
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 14
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229940075420 xanthine Drugs 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 5
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 5
- 229960003459 allopurinol Drugs 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000046198 Triteleia hyacinthina Species 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical group C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940082820 nelumbo nucifera leaf extract Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an active substance composition for reducing uric acid and application thereof, the composition takes an extract of Ampelopsis grossedentata leaves and an extract of lotus leaves as active ingredients, experimental results show that the composition obviously reduces the serum uric acid level of a hyperuricemia model caused by potassium oxonate, can be applied to the development of functional foods and medicines for reducing uric acid, and has simple preparation process and high safety.
Description
Technical Field
The invention belongs to the field of functional food and pharmacy, and relates to a functional product for assisting in reducing uric acid by utilizing a Ampelopsis grossedentata leaf extract.
Background
The end product of purine metabolism is uric acid, most of uric acid produced by purine metabolism in a normal state is discharged out of a body through a kidney and a biliary tract, and if the purine metabolic system in the body is disturbed, the uric acid level of the end product is increased, so that hyperuricemia is caused. The international diagnosis of hyperuricemia is defined as: under normal purine diet, the fasting blood uric acid level of the male is more than 420 mu mol/L and the female is more than 360 mu mol/L for 2 times on non-same day. With the improvement of living standard, various high protein diets enter dining, the ingestion of purine in protein foods is greatly increased in modern people, the prevalence rate of hyperuricemia shows a gradually rising trend in recent years, and the prevalence age of hyperuricemia shows a gradually younger trend.
Hyperuricemia is a cause of diseases and a manifestation of an initial stage, when the concentration of blood uric acid is too high and/or under an acidic environment, uric acid can be separated out and crystallized and deposited on tissues such as bone joints, kidneys and subcutaneous tissues to cause histopathological changes, so that gouty arthritis, gouty kidneys, tophus and the like are caused. Gout imposes a physiological burden on individuals, and meanwhile, serious gout symptoms also affect normal work, so that immeasurable economic loss is caused. Thus, control of the source of gout and its symptoms is imminent.
Allopurinol, probenecid, colchicine, non-steroidal anti-inflammatory drugs, glucocorticoids and the like are common anti-gout drugs at present and occupy a leading position in the anti-gout drug market. However, these drugs have serious adverse reactions, especially have great toxic and side effects on the kidney and related organs, are difficult to take for a long time, and are limited in clinical application. Therefore, the development of the novel active substance with low toxic and side effects and uric acid reduction from food sources has important significance.
Ampelopsis grossedentata is an perennial woody vine of the genus Ampelopsis of the family Vitaceae. The application of Ampelopsis grossedentata leaves is recorded in tea Jing, and although the Ampelopsis grossedentata is abundant in resources, most of the Ampelopsis grossedentata leaves are mainly used for preparing rough tea beverage products and are not high in development and utilization degree. The ampelopsis grossedentata leaves contain various chemical components such as flavonoids, phenols, steroids, polysaccharides, volatile oils and the like, and researches show that the ampelopsis grossedentata leaves and the extract thereof have various pharmacological activities such as anti-inflammation, antibiosis, liver function protection, blood sugar and lipid reduction, antithrombotic, antitumor, atherosclerosis resistance, cardiovascular protection and the like. Dihydromyricetin is a main flavonoid component in ampelopsis grossedentata leaves and is one of main components playing pharmacological actions in the ampelopsis grossedentata leaves. Researches find that the dihydromyricetin in the ampelopsis grossedentata leaves has good effect of treating hyperuricemia, and can also correct disordered renal functions and improve the pathological changes of the kidney.
The lotus leaf is a traditional Chinese medicine with homology of medicine and food, has biological activities of lipid reduction, oxidation resistance and the like, has no obvious toxic or side effect and has higher safety. The lotus leaves mainly contain chemical components such as alkaloids, flavonoids, volatile oil and the like, the nuciferine is aporphine alkaloid which is a main medicinal component in the lotus leaves, can stimulate insulin secretion, prevent and treat atherosclerosis and non-alcoholic fatty liver, and has obvious pharmacological activity in the aspects of relieving hyperuricemia renal inflammation and protecting kidney. Both the lotus leaf lipid-lowering soup and the ginseng and lotus leaf lipid-lowering liver soup which take lotus leaves as main medicines have the effect of lowering the serum uric acid level clinically, but the prescription has numerous medicines and insufficient safety, so the long-term taking is not suitable.
Chinese patent CN114224957A discloses a composition for reducing uric acid, which comprises an Ampelopsis grossedentata extract and a Cordyceps militaris extract. Although the patent suggests that the ampelopsis grossedentata extract contains the active substance dihydromyricetin for reducing uric acid, and the ampelopsis grossedentata extract has a certain xanthine oxidase inhibiting effect in vitro, the experimental results provided by the patent also show that the ampelopsis grossedentata extract cannot reduce the blood uric acid level of patients with hyperuricemia, and the reduction amplitude of the blood uric acid of the patients with hyperuricemia after the composition is administered is only about 17% at most.
Chinese patent CN109170059A discloses a tea bag made of lotus leaves, blueberry leaves, liquorice and auxiliary materials. Although the patent suggests that the blueberry leaves in the tea bag formula can enhance the inhibition effect of the lotus leaves on xanthine oxidase, the test is only based on the efficacy of the tea soup on the in vitro xanthine oxidase inhibition rate, and under the condition of lacking pharmacological experimental verification, the conclusion about the reduction of the uric acid level of the human body is only a conjecture made under the condition of lacking reliable experimental evidence, so the reference is difficult to refer to.
Disclosure of Invention
The invention aims to provide an active substance composition for reducing uric acid and application thereof, and solves the problem of insufficient efficacy of a Ampelopsis grossedentata leaf extract in developing functional foods and medicines for assisting in reducing uric acid.
In order to achieve the purpose, the invention adopts the following technical scheme:
a uric acid reducing active substance composition comprises 5-15 parts by weight of Ampelopsis grossedentata leaf extract and 1-14 parts by weight of lotus leaf extract.
Preferably, in the composition, the lotus leaf extract accounts for 1-8 parts.
Preferably, the ampelopsis grossedentata leaf extract is prepared by carrying out water extraction, concentration and drying on the ampelopsis grossedentata leaves, and the specific preparation method comprises the following steps: extracting dried Ampelopsis grossedentata leaves with 10-20 times of water for 2-4 times (at 70-100 deg.C) for 1-3 hr, mixing extractive solutions, concentrating under normal pressure (at 70-100 deg.C), and drying (at 40-80 deg.C for 24-48 hr).
Preferably, the content of dihydromyricetin in the ampelopsis grossedentata leaf extract is 20% -40%.
Preferably, the lotus leaf extract is prepared by carrying out water extraction, concentration and drying on lotus leaves, and the specific preparation method comprises the following steps: extracting dried folium Nelumbinis with 20-40 times of water for 2-4 times (extraction temperature is 70-100 deg.C) for 1-2 hr, mixing extractive solutions, concentrating under normal pressure (temperature is 70-100 deg.C), and drying (temperature is 40-80 deg.C, and time is 24-48 hr).
Preferably, the content of nuciferine in the lotus leaf extract is 1% -10%.
Preferably, the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is (1-4) to (1-2).
Preferably, the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is 2-4:1.
Preferably, in the composition, the mass fraction of the ampelopsis grossedentata leaf extract is more than or equal to 40%, and the mass fraction of the lotus leaf extract is less than or equal to 60%.
Preferably, the composition consists of 40-94% of the ampelopsis grossedentata leaf extract and 6-60% of the lotus leaf extract in percentage by mass.
Preferably, the composition consists of 65-85% of the ampelopsis grossedentata leaf extract and 15-35% of the lotus leaf extract in percentage by mass.
Preferably, the composition consists of 80% of the ampelopsis grossedentata leaf extract and 20% of the lotus leaf extract in parts by mass.
The preparation with the function of assisting in reducing uric acid comprises the composition and auxiliary materials by weight, wherein the auxiliary materials comprise 40-100 parts of isomalt and 0.01-0.1 part of sucralose.
Preferably, the formulation is in a dosage form selected from a solid beverage, a tablet, a pill or a liquid drink.
Preferably, the dosage of the preparation is 1-12g per person per day.
The preparation method of the preparation with the function of assisting in reducing uric acid comprises the following steps:
sieving Ampelopsis grossedentata leaf extract, folium Nelumbinis extract and adjuvants respectively, mixing, and sequentially making soft material, granulating, drying and grading.
The application of the active substance composition for reducing uric acid in preparing a medicament for treating hyperuricemia.
Preferably, the Ampelopsis grossedentata leaf extract is a competitive inhibitor of xanthine oxidase.
Preferably, the lotus leaf extract synergistically cooperates with the Ampelopsis grossedentata leaf extract to inhibit the activity of xanthine oxidase and enhance the uric acid lowering effect of the Ampelopsis grossedentata leaf extract.
The invention has the beneficial effects that:
according to the auxiliary treatment effect of dihydromyricetin in the Ampelopsis grossedentata leaves on the resistance to the hyperuricemia, the active substance composition is enabled to generate the obvious effect of reducing the uric acid by matching the Ampelopsis grossedentata leaf extract (such as an aqueous extract) with the lotus leaf extract (such as an aqueous extract), and the composition can enable the reduction amplitude of the uric acid to reach more than 40% through the verification of a hyperuricemia model. Meanwhile, when the composition is used for a preparation, the composition has the advantages of simple active ingredient formula and few auxiliary material components, and can provide a safe and effective effect of resisting hyperuricemia.
Furthermore, the uric acid reducing active substance composition has stronger inhibition effect on xanthine oxidase activity by introducing the lotus leaf extract with a certain proportion, can obviously improve the symptom of abnormal rise of serum uric acid level in hyperuricemia, and achieves better uric acid reducing effect.
Detailed Description
The present invention is further illustrated by the following examples, which are provided only for the purpose of illustration and are not intended to limit the scope of the present invention.
The invention determines that the Ampelopsis grossedentata leaves and lotus leaves have stronger synergistic inhibition effect on xanthine oxidase in vitro by preliminarily screening 22 medicinal and edible raw materials with the function of reducing uric acid, wherein the 22 medicinal and edible raw materials specifically comprise: corn stigma, sophora flower bud, peony, chrysanthemum, lotus leaf, honeysuckle, chinese yam, reed rhizome, dried houttuynia, gardenia, dandelion, pawpaw, cassia seed, white hyacinth bean, coix seed, tuckahoe, wax gourd peel, broccoli seed, celery seed, euglena, inulin and ampelopsis grossedentata leaf. The efficacy of the combination of Ampelopsis grossedentata leaf extract and Nelumbo nucifera leaf extract in combating hyperuricemia is examined below.
Preparation of Ampelopsis grossedentata leaf extract and lotus leaf extract
1.1 preparation method of Ampelopsis grossedentata leaf extract
Soaking 10kg of dried Ampelopsis grossedentata leaves in 20 times (L) of purified water for 20min, heating to 100 deg.C, extracting for 2 times (1 hr each time), filtering, mixing filtrates to obtain extractive solution, concentrating the extractive solution (at normal pressure and 100 deg.C), and drying at 80 deg.C for 36 hr to obtain 2.5kg of Ampelopsis grossedentata leaf extract.
1.2 identification of the Components of the Ampelopsis grossedentata leaf extract
Taking a Ampelopsis grossedentata leaf extract sample, and detecting the content of dihydromyricetin in the Ampelopsis grossedentata leaf extract sample: the liquid chromatography (column temperature 30 ℃, detection wavelength 289 nm) is adopted, the dihydromyricetin is used as a reference substance, a mobile phase is added for dilution, a sample solution of 0.05mg/mL is prepared, a methanol-0.05% phosphoric acid solution (methanol: 0.05% phosphoric acid solution volume ratio = 35) is used as the mobile phase for elution, and the content of the dihydromyricetin in the sample is finally measured to be 24.31% through linear relation investigation and peak area measurement.
1.3 preparation of Lotus leaf extract
Soaking 10kg of dried folium Nelumbinis in 40 times (L) of purified water for 20min, heating at 80 deg.C for 2 times, extracting for 1 hr each time, filtering, mixing filtrates to obtain extractive solution, concentrating the extractive solution (at 100 deg.C and normal pressure), and drying at 80 deg.C for 36 hr to obtain 1.2kg of folium Nelumbinis extract.
1.4 ingredient identification of Lotus leaf extract
Taking a lotus leaf extract sample, and detecting the nuciferine content: the method comprises the following steps of (1) performing liquid chromatography (column temperature is 30 ℃, detection wavelength is 270 nm), using nuciferine as a reference substance, adding methanol for dilution, preparing a sample solution of 0.5mg/mL, using acetonitrile-water solution (each 1000mL of the water solution contains 25.5mL of triethylamine and 11mL of glacial acetic acid; the volume ratio of acetonitrile to the water solution is = 49) as a mobile phase for elution, and finally determining the nuciferine content in the sample to be 1.21% through linear relation examination and peak area determination.
(II) in vitro assay for xanthine oxidase inhibition
2.1 preparation of reagent solutions
2.1.1 preparation of test solution set:
(1) 6.7mg of the lotus leaf extract and 13.4mg of the ampelopsis grossedentata leaf extract (lotus leaf extract: ampelopsis grossedentata leaf extract = 1) were precisely weighed into a 50mL measuring flask, and the volume was determined with absolute ethanol.
(2) 3.35mg of the lotus leaf extract and 13.4mg of the ampelopsis grossedentata leaf extract (lotus leaf extract: ampelopsis grossedentata leaf extract =1, 4 w/w) were precisely weighed into a 50mL measuring flask, and the volume was fixed with absolute ethanol.
(3) 13.4mg of the lotus leaf extract and 6.7mg of the ampelopsis grossedentata leaf extract (lotus leaf extract: ampelopsis grossedentata leaf extract = 2) were precisely weighed into a 50mL measuring flask, and the volume was determined with absolute ethanol.
2.1.2 preparation of xanthine solution:
15.27mg of xanthine was precisely weighed, and 10mL of 0.1mol/L sodium hydroxide solution was added thereto, and the mixture was dissolved sufficiently, and then the volume was adjusted to 100mL with PBS (pH 7.5), whereby 1mmol/L xanthine solution was obtained.
2.1.3 preparation of xanthine oxidase solution:
xanthine oxidase 0.2mg was weighed out precisely, dissolved in PBS (pH 7.5) and fixed to a volume of 10mL in a volumetric flask to obtain a xanthine oxidase solution of 20. Mu.g/mL.
2.2 the inhibitory effect of the composition of the extracts of Ampelopsis grossedentata leaves and Nelumbo nucifera leaves in different proportions on xanthine oxidase
Negative blank group: 1.2mL of distilled water was precisely aspirated, and the mixture was thoroughly mixed with 2.8mL of PBS (pH 7.5) and 1mL of xanthine solution to prepare a mixture for absorbance measurement.
Sample blank group: 0.1mL of each of the test solutions (1), (2) and (3) was precisely aspirated, and then thoroughly mixed with 1.1mL of distilled water, 2.8mL of PBS (pH 7.5) and 1mL of xanthine solution to prepare a mixture for absorbance measurement.
Negative group: precisely sucking 2.8mL PBS (pH 7.5), mixing with 1mL distilled water and 0.2mL xanthine oxidase solution uniformly, incubating in 37 deg.C water bath for 15min, adding 1mL xanthine solution, mixing thoroughly, reacting at 25 deg.C, and measuring absorbance at 1min, 2min, 3min, 4min, 5min, 6min, 7min, 8min, 9min, and 10 min.
Sample solution group: precisely sucking 0.1mL of test solution (1), (2) and (3), respectively, mixing with 0.9mL of distilled water, 2.8mL of PBS (pH 7.5) and 0.2mL of xanthine oxidase solution, incubating in 37 deg.C water bath for 15min, adding 1mL of xanthine solution, mixing thoroughly, starting reaction at 25 deg.C, and measuring absorbance at 1min, 2min, 3min, 4min, 5min, 6min, 7min, 8min, 9min and 10min, respectively.
2.3 results of the experiment
Detecting the xanthine oxidase inhibition activity of a test sample, wherein the calculation formula of the xanthine oxidase inhibition rate is as follows:
inhibition = [ (Rp-Rs)/Rp ]. Times.100%
In the formula, rs and Rp represent the reaction rates (the slope is the reaction rate and is determined by the slope of the absorbance standard curve at different times) of the sample (the sample blank is subtracted) and the negative (the negative blank is subtracted), respectively.
The results showed that by measuring the xanthine oxidase inhibition ratios of the test samples, the test sample solutions (1), (2), and (3) had xanthine oxidase inhibition ratios of 51.4%, 55.3%, and 37.23%, respectively, i.e., when the lotus leaf extract, i.e., the ampelopsis grossedentata leaf extract =1:4, the combination of the lotus leaf extract and the ampelopsis grossedentata leaf extract (1:4) had the strongest xanthine oxidase inhibition effects, and the inhibition effects of the combination were stronger than the inhibition effects of the lotus leaf extract and the ampelopsis grossedentata leaf extract alone (23.15%, 49.55%).
Pharmacological experiment of effect of composition on reducing uric acid of hyperuricemia mice
3.1 test drugs
Dissolving folium Nelumbinis extract (HY, 0.18 g/kg), ampelopsis grossedentata leaf extract (PTY, 0.18 g/kg), and composition of folium Nelumbinis extract and Ampelopsis grossedentata leaf extract (1:4) (HY + PTY (1:4), 0.18 g/kg) in distilled water, and performing intragastric administration at administration volume of 0.1mL/10 g.
3.2 Positive control drugs
The allopurinol tablet is ground and dissolved in distilled water (administered by gavage at a dose of 10mg/kg/d, administration volume 0.1mL/10 g).
3.3 grouping and Experimental methods
Hypoxanthine is a precursor substance of body uric acid, and injection of hypoxanthine can cause accumulation of uric acid, thereby inducing hyperuricemia; potassium oxonate can inhibit uricase from decomposing uric acid, so that the decomposition of uric acid in a body is reduced, the uric acid level is continuously increased, and hyperuricemia is induced. The two are combined for modeling, so that a hyperuricemia renal function injury model can be remarkably induced.
The experiment was started after confirming that the health status of animals was good by adaptively feeding 82 male mice of SPF-class Kunming species for 4 days. Mice were randomly divided into 7 groups by body weight, namely Blank control (Blank) group, vehicle control (VE) group, model (Model) group, allopurinol (Allopurinol) group, lotus leaf extract (HY) group, HY + PTY (1:4) group, and ampelopsis grossedentata leaf extract (PTY) group, wherein Allopurinol group was 20, model group was 12, and the remaining group was 10.
Except for a blank control group and a solvent control group, the rest groups are administered with hypoxanthine continuously for 7 days by intragastric administration according to the dose of 500mg/kg, the former six days are administered with test drugs and positive control drugs of the corresponding group by intragastric administration at intervals of 30min every day, all mice are fasted in the sixth evening, and the seventh day is administered with hypoxanthine 30min last, the rest groups are injected with 300mg/kg of oteracil potassium in the abdominal cavity, and the test drugs and the positive control drugs of the corresponding group are administered with intragastric administration at intervals of 20 min. The vehicle control group was gavaged with an equal volume of 0.5% sodium carboxymethylcellulose aqueous solution and given with 0.5% sodium carboxymethylcellulose physiological saline solution by intraperitoneal injection. The blank control group was normally bred without any treatment.
1h after the intraperitoneal injection of the oteracil potassium is finished, blood is taken from eye sockets, the blood is placed in a clean centrifugal tube, standing is carried out for 2h at room temperature, the blood is centrifuged for 10min at the rotating speed of 3000rpm to obtain serum, and the serum is respectively filled in a 200 mu L centrifugal tube. The uric acid kit is used for detecting the content of blood uric acid in serum.
3.4 results of the experiment
As can be seen from table 1: after 7 days of modeling of the hyperuricemia Model, compared with a solvent control group, the Model group (Model) has extremely obviously increased blood uric acid value (P < 0.001); after 7 days of administration, the allopurinol group had a very significant decrease in blood uric acid level (P < 0.0001) compared with the Model group (Model), indicating successful modeling. 7 days after the administration, the blood uric acid value of the lotus leaf extract group (0.18 g/kg) is remarkably reduced (P < 0.05) compared with that of the model group; compared with the model group, the ampelopsis grossedentata leaf extract group (0.18 g/kg) has extremely significant reduction of the blood uric acid value (P < 0.01); HY + PTY (1:4) group (0.18 g/kg) showed a significant decrease in blood uric acid levels compared to the model group (P < 0.001). The blood uric acid values of the lotus leaf extract group, the Ampelopsis grossedentata leaf extract group and the HY + PTY (1:4) group are 203.01, 171.79 and 140.99 mu mol/L respectively, and after the composition of the lotus leaf extract and the Ampelopsis grossedentata leaf extract (1:4) is given, the blood uric acid value is obviously lower than the blood uric acid values after the lotus leaf extract (with statistical difference, P < 0.01) and the Ampelopsis grossedentata leaf extract (with statistical difference, P < 0.05) are given separately.
TABLE 1 statistics of animal experimental groups and Uric Acid (UA) lowering effect of different test substances
Note: comparing P <0.05, P <0.01, P <0.001, P < 0.0001 to model groups; # P <0.01 compared with HY group; p <0.05 compared with PTY group.
Pharmacological experiment of uric acid reducing effect of different administration doses of composition on hyperuricemia mice
4.1 test drug formulation
Dissolving the composition of folium Nelumbinis extract and Ampelopsis grossedentata leaf extract (1:4) in distilled water, respectively, and making into low, medium and high dosage (0.09, 0.18, 0.36 g/kg) medicinal liquid. The administration volume of the mixture is 0.1mL/10 g.
4.2 Positive control drugs
Allopurinol tablets were crushed and dissolved in distilled water (administered by gavage at a dose of 10mg/kg/d, administration volume 0.1mL/10 g).
4.3 grouping and Experimental methods
70 SPF male Kunming mice were bred adaptively for 4 days, and the experiments were started after confirming the health status of the animals. Mice were randomized into 7 groups of 10 mice per group by body weight. Namely Blank control (Blank) group, solvent control (VE) group, model (Model) group, allopurinol (Allopurinol) group, and low, medium and high dose group of the combination of lotus leaf extract and ampelopsis grossedentata leaf extract (1:4) (HY + PTY (1:4)).
Except for a blank control group and a solvent control group, the rest groups are administered with hypoxanthine continuously for 7 days by intragastric administration according to the dose of 500mg/kg, the former six days are administered with test drugs and positive control drugs of the corresponding group by intragastric administration at intervals of 30min every day, all mice are fasted in the sixth evening, and the seventh day is administered with hypoxanthine 30min last, the rest groups are injected with 300mg/kg of oteracil potassium in the abdominal cavity, and the test drugs and the positive control drugs of the corresponding group are administered with intragastric administration at intervals of 20 min. The vehicle control group was gavaged with an equal volume of 0.5% sodium carboxymethylcellulose aqueous solution and given with 0.5% sodium carboxymethylcellulose physiological saline solution by intraperitoneal injection. The blank control group was not treated at all.
1h after the intraperitoneal injection of the oteracil potassium is finished, blood is taken from eye sockets, the blood is placed in a clean centrifugal tube, standing is carried out for 2h at room temperature, the blood is centrifuged for 10min at the rotating speed of 3000rpm to obtain serum, and the serum is respectively filled in a 200 mu L centrifugal tube. The uric acid kit is used for detecting the content of blood uric acid in serum.
4.4 results of the experiment
As can be seen from table 2: after 7 days of modeling of the hyperuricemia Model, compared with a solvent control group, the blood uric acid value of the Model group is increased extremely remarkably (P is less than 0.001); after 7 days of administration, the uric acid level was extremely significantly decreased (P < 0.0001) in the allopurinol group compared with the Model group. 7 days after administration, the HE + PTY (1:4) group with low, medium and high doses (0.09, 0.18, 0.36 g/kg) showed a significant or very significant decrease in serum uric acid values (P <0.05 or P < 0.001) compared with the model group.
TABLE 2 statistics of Uric Acid (UA) lowering effect of animal experimental groups and different dosage compositions
Note: p <0.05, P <0.001, P < 0.0001 compared to model groups.
The results show that the mouse hyperuricemia model is established by combining hypoxanthine intragastric administration and intraperitoneal injection of potassium oxonate, and the results prove that compared with single extracts (lotus leaf extract and Ampelopsis grossedentata leaf extract), the composition of the lotus leaf extract and the Ampelopsis grossedentata leaf extract (1:4) has better treatment effect on hyperuricemia, and the uric acid reducing effect of the composition is related to the improvement of the inhibition effect of the composition on xanthine oxidase.
(V) product development based on composition
5.1 Process for producing functional food
(1) Formulation (by weight)
The composition (lotus leaf extract: ampelopsis grossedentata leaf extract = 1:4), isomalt and sucralose are respectively 15 parts (wherein, the lotus leaf extract is 3 parts, and the Ampelopsis grossedentata leaf extract is 12 parts), 80 parts and 0.06 part.
The preparation process of the pressed candy comprises the following steps: sieving the components in the formula, mixing uniformly, preparing a soft material, granulating, drying, granulating, tabletting and inspecting the quality.
(2) Formulation (by weight)
The composition (lotus leaf extract: ampelopsis grossedentata leaf extract = 1:4), isomalt and sucralose are 15 parts, 80 parts and 0.06 part respectively.
The preparation process of the solid beverage comprises the following steps: sieving the formula components, mixing, preparing soft materials, granulating, drying, grading, sterilizing and packaging.
5.2 dosage of functional food
The composition determined by the pharmacological experiments can effectively reduce the dosage (0.09-0.36 g/kg) of the blood uric acid, and the dosage of the composition is 0.45-1.8g per day according to the conversion of the dosage of the composition in a human body, so that the composition can be used for the adjuvant treatment of hyperuricemia.
5.3 quality control of functional foods
Taking the prepared solid beverage and tablet candy containing the composition as samples, detecting the content of total flavonoids, extracting with ethanol, adsorbing with polyamide powder, eluting with methanol, purifying, taking rutin as a reference sample, measuring absorbance of the total flavonoids at 360nm by spectrophotometry, and quantifying by standard curve method. Finally, the content of the total flavone in the sample is measured to be more than or equal to 100mg/100g.
In conclusion, the invention takes the extracts of Ampelopsis grossedentata leaves and lotus leaves as main functional components, inhibits the activity of xanthine oxidase in the body and reduces the generation of blood uric acid. Experiments show that the compatibility of the lotus leaf extract and the ampelopsis grossedentata leaf extract can not only strengthen the nutrition effect, but also achieve the purpose of obviously improving the functionality (such as more obvious uric acid reducing effect). Meanwhile, the ampelopsis grossedentata leaves and the lotus leaves are all derived from plants, so that the method is rich in resources, high in safety and wide in development prospect.
Claims (10)
1. A uric acid reducing active substance composition is characterized in that: the composition comprises 5-15 parts by weight of ampelopsis grossedentata leaf extract and 1-14 parts by weight of lotus leaf extract.
2. The uric acid lowering active substance composition according to claim 1, characterized in that: the Ampelopsis grossedentata leaf extract is prepared by extracting Ampelopsis grossedentata leaves with water, concentrating, and drying.
3. The uric acid lowering active substance composition according to claim 1, characterized in that: the lotus leaf extract is prepared by extracting lotus leaves with water, concentrating and drying.
4. The uric acid lowering active substance composition according to claim 1, characterized in that: the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is (1-4) to (1-2).
5. The active substance composition for reducing uric acid as defined in claim 1, wherein: the mass ratio of the ampelopsis grossedentata leaf extract to the lotus leaf extract in the composition is 2-4:1.
6. The uric acid lowering active substance composition according to claim 1, characterized in that: in the composition, the mass fraction of the Ampelopsis grossedentata leaf extract is more than or equal to 40%, and the mass fraction of the lotus leaf extract is less than or equal to 60%.
7. The uric acid lowering active substance composition according to claim 1, characterized in that: the composition comprises 40-94% of ampelopsis grossedentata leaf extract and 6-60% of lotus leaf extract by mass fraction.
8. A preparation with the function of assisting in reducing uric acid is characterized in that: the preparation comprises active substance composition for reducing uric acid and auxiliary materials by weight, wherein the composition comprises 5-15 parts of Ampelopsis grossedentata leaf extract and 1-14 parts of lotus leaf extract, and the auxiliary materials comprise 40-100 parts of isomalt and 0.01-0.1 part of sucralose.
9. A method for preparing the preparation with the function of assisting in reducing uric acid according to claim 8, which is characterized in that: the method comprises the following steps:
sieving Ampelopsis grossedentata leaf extract, folium Nelumbinis extract and adjuvants respectively, mixing, making soft material, granulating, drying and grading.
10. Use of the uric acid lowering active substance composition according to claim 1 in the preparation of a medicament for the treatment of hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211071108.0A CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211071108.0A CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115444893A true CN115444893A (en) | 2022-12-09 |
| CN115444893B CN115444893B (en) | 2023-07-07 |
Family
ID=84300756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211071108.0A Active CN115444893B (en) | 2022-09-02 | 2022-09-02 | Uric acid reducing active substance composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115444893B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116210900A (en) * | 2022-12-29 | 2023-06-06 | 抱朴生命科技(广州)有限公司 | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016071505A1 (en) * | 2014-11-07 | 2016-05-12 | Danmarks Tekniske Universitet | Microbial production of the flavonoids garbanzol, resokaempferol and fisetin |
| CN106031725A (en) * | 2016-05-18 | 2016-10-19 | 广东奇方药业有限公司 | Drug application of nuciferine and analogue thereof |
| JP2018043985A (en) * | 2016-09-07 | 2018-03-22 | 株式会社ファンケル | Ampelopsin-containing composition for reducing urine acid level in blood |
| CN108686123A (en) * | 2018-07-16 | 2018-10-23 | 何利均 | A kind of Chinese medicine for treating gout |
| CN110420293A (en) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | The plant composition and plant composition solid particle for treating hyperuricemia and gout |
| CN111973704A (en) * | 2020-08-11 | 2020-11-24 | 中山市中智药业集团有限公司 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
| CN113115942A (en) * | 2021-06-08 | 2021-07-16 | 安徽壹心德生物科技有限公司 | Blood fat reducing dietary formula and processing technology thereof |
| JP2021109869A (en) * | 2020-01-09 | 2021-08-02 | オリザ油化株式会社 | AGE production inhibitor |
| CN114470072A (en) * | 2022-01-27 | 2022-05-13 | 湖北省农业科学院中药材研究所 | Ampelopsis grossedentata extract, preparation method thereof and application thereof in preparation of diuretic drugs |
-
2022
- 2022-09-02 CN CN202211071108.0A patent/CN115444893B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016071505A1 (en) * | 2014-11-07 | 2016-05-12 | Danmarks Tekniske Universitet | Microbial production of the flavonoids garbanzol, resokaempferol and fisetin |
| CN106031725A (en) * | 2016-05-18 | 2016-10-19 | 广东奇方药业有限公司 | Drug application of nuciferine and analogue thereof |
| JP2018043985A (en) * | 2016-09-07 | 2018-03-22 | 株式会社ファンケル | Ampelopsin-containing composition for reducing urine acid level in blood |
| CN108686123A (en) * | 2018-07-16 | 2018-10-23 | 何利均 | A kind of Chinese medicine for treating gout |
| CN110420293A (en) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | The plant composition and plant composition solid particle for treating hyperuricemia and gout |
| JP2021109869A (en) * | 2020-01-09 | 2021-08-02 | オリザ油化株式会社 | AGE production inhibitor |
| CN111973704A (en) * | 2020-08-11 | 2020-11-24 | 中山市中智药业集团有限公司 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
| CN113115942A (en) * | 2021-06-08 | 2021-07-16 | 安徽壹心德生物科技有限公司 | Blood fat reducing dietary formula and processing technology thereof |
| CN114470072A (en) * | 2022-01-27 | 2022-05-13 | 湖北省农业科学院中药材研究所 | Ampelopsis grossedentata extract, preparation method thereof and application thereof in preparation of diuretic drugs |
Non-Patent Citations (6)
| Title |
|---|
| 卢忠英，等: "藤茶提取物中二氢杨梅素对大鼠急性痛风性关节炎模型的影响", 中国现代应用药学, vol. 32, no. 04, pages 396 - 399 * |
| 周洁，等: "中药活性成分降尿酸作用机制研究进展", 中国药理学通报, vol. 34, no. 01, pages 19 - 22 * |
| 张艺芳，等: "痛风停药效学实验研究", 内蒙古中医药, vol. 33, no. 25, pages 79 - 80 * |
| 杨新跃，等: "藤茶和荷叶提取物对高脂血症大鼠降血脂作用的实验研究", 中国比较医学杂志, vol. 15, no. 05, pages 281 - 284 * |
| 郭花斌，等: "药食两用中草药在防治高尿酸血症上的研究进展", 世界最新医学信息文摘, vol. 18, no. 86, pages 50 - 51 * |
| 陈吼，等: "复方鹿衔草总黄酮纯化工艺优选", 现代中医药, vol. 33, no. 02, pages 89 - 91 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116210900A (en) * | 2022-12-29 | 2023-06-06 | 抱朴生命科技(广州)有限公司 | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof |
| CN116210900B (en) * | 2022-12-29 | 2024-01-30 | 抱朴生命科技(广州)有限公司 | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115444893B (en) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| KR100425022B1 (en) | Ginseng extract and pharmaceutical composition containing it | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| WO2016099043A1 (en) | Drink composition for hangover relief and liver function improvement | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| CN111528470A (en) | Preparation method of calcium roxburgh rose complex, product and application thereof | |
| US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
| CN115444893A (en) | Active substance composition for reducing uric acid and application thereof | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN111166820B (en) | Traditional Chinese medicine composition containing fingered citron, preparation and application | |
| JP2003212783A (en) | Medicament or functional food for suppressing rise in blood glucose level or blood pressure | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| EP3025593A1 (en) | Nutraceutical compound for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia | |
| KR100471340B1 (en) | A new process for enhancing the efficacies of Ginseng | |
| KR100505780B1 (en) | Healthy food composition having efficacy of anti-diabetic and its process | |
| CN104374890B (en) | A kind of Ilex kudincha C. J. Tseng extract | |
| CN100434085C (en) | Process for removing toxic component from oleum fructus bruceae | |
| KR100453542B1 (en) | Food additive and health foods containing Ginseng extract | |
| CN114292302B (en) | Compound extracted from wampee leaves, and preparation process and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| KR102659899B1 (en) | Nutraceutical composition comprising milk thistle extract and rhodiola rosea extract, and method of making the same | |
| CN103054848B (en) | Pharmaceutical composition for preventing or treating cardiovascnlar and cerebrovascular diseases | |
| EP4434532A1 (en) | Phosphodiesterase 5 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |